Vaccine Company

Vaccine Company is a private U.S. biotechnology company focused on prophylactic vaccines for infectious diseases. Publicly visible evidence indicates the company has advanced VXCO-100, a SARS-CoV candidate vaccine, into completed Phase 1 studies in the United States and South Africa, and it also received an ARPA-H award for Project A-FAVE, which is aimed at broad flavivirus antigen discovery and vaccine candidate evaluation. The company appears to be operating under the legal name Vaccine Company, Inc. and is associated with Bethesda, Maryland. Its disclosed pipeline is narrow, with limited public information on additional named assets, but its work spans coronavirus and flavivirus vaccine development. The organization appears to combine vaccine R&D with computational antigen-design capabilities for multi-virus vaccine discovery.